Q-omics provides the consensus-scored RNY1P14 profile across patient tissues and cancer cell-line models. RNY1P14 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNY1P14 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, RNY1P14 RNA expression shows 7,453 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, KIRC, and COAD as cancer lineages where RNY1P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY1P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY1P14 survival associations across molecular data types. RNY1P14 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY1P14 RNA expression–survival associations across cancer types. High RNY1P14 expression shows unfavorable associations in ACC, LIHC, LAML and KICH, but favorable associations in BRCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNY1P14 RNA expression.
This table summarizes RNY1P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNY1P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY1P14 shows lower tumor expression in KIRC and higher tumor expression in BRCA and LUSC. The KIRC box plot shows higher RNY1P14 RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p = .019).
This table shows molecular features associated with RNY1P14 in patient tissues and cancer cell lines. In patient samples, RNY1P14 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
